Patents Assigned to GlaxoSmithKline LLC
  • Patent number: 10035779
    Abstract: The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline, LLC
    Inventors: Duke M. Fitch, Antony N. Shaw, Kenneth Wiggall
  • Patent number: 9926570
    Abstract: The present invention relates to genetically modified host cells, in particular yeast cells, comprising at least one isolated polynucleotide encoding a Killer Expression protease (Kex2p) or a fragment and/or variant thereof which has at least one Kex2p functional activity and at least one isolated polynucleotide encoding a Protein Disulfide-Isomerase (Pdi1) or a fragment and/or variant thereof which has at least one Pdi functional activity.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: March 27, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Yonghwan Jin, Yuan Zhu
  • Patent number: 9901479
    Abstract: Aspects of the present invention relate to methods of making an external nasal dilator amenable to continuous and automated manufacture. For example, in one embodiment of the method, a roll of a three-layered material is used as the starting material, the three layers consisting substantially and respectively of (1) a resilient sheet, (2) an adhesive-protecting sheet, and (3) an adhesive layer between the resilient sheet and the adhesive-protecting sheet. A series of dies are used to cut the three-layered material into the appropriate shape and (when necessary) to impress grooves in the resilient sheet.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 27, 2018
    Assignee: GlaxoSmithKline, LLC
    Inventors: Randel B. Holmes, Dennis White
  • Patent number: 9868761
    Abstract: A method for purifying a protein using a simplified, sodium chloride-free buffer system that consists of two components (acid and base pairs) for appropriate solution pH control; and a third component for ionic strength control, where the third component is the sodium salt conjugate base.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: January 16, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Kent E. Goklen, Eric J. Suda, Antonio Raul Ubiera
  • Patent number: 9861627
    Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 9, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
  • Patent number: 9834600
    Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 5, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Fredrick E. Hargreave, Giampietro Ventresca
  • Patent number: 9795619
    Abstract: The present invention relates to long acting pharmaceutical compositions of betulin derivatives or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: December 14, 2013
    Date of Patent: October 24, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Shenshen Cai, Brian Alvin Johns, Andrew Spaltenstein
  • Patent number: 9738658
    Abstract: This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, exce
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: August 22, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Mui Cheung, Raghuram S. Tangirala
  • Patent number: 9675548
    Abstract: Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: June 13, 2017
    Assignee: GlaxoSmithKline, LLC
    Inventor: Li-Lan Chen
  • Patent number: 9663533
    Abstract: Thienopyridone compounds of formula (I): or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: May 30, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Dominique Amans, Paul Bamborough, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Matthew John Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
  • Patent number: 9662336
    Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 30, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Patent number: 9649307
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: May 16, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: William Henry Miller, Xinrong Tian, Sharad Kumar Verma
  • Patent number: 9642995
    Abstract: The present invention relates to an external nasal dilator, more specifically to an improved external nasal dilator, which provides a focused and efficient spring force to the outer wall tissues of a first and second nasal passages.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 9, 2017
    Assignee: GlaxoSmithKline, LLC
    Inventors: Gustav R. Fenton, Snigdha Mishra
  • Patent number: 9624174
    Abstract: Compounds of Formula (I) are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), useful in the treatment of obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 18, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Mui Cheung, Raghuram S. Tangirala
  • Patent number: 9624261
    Abstract: The invention is directed to a method for producing a polypeptide composition comprising: combining a polypeptide with a volatile additive to form a liquid mixture and lyophilizing the liquid mixture to obtain a lyophilized polypeptide composition.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: April 18, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Kent E. Goklen, Eric J. Suda, Antonio Raul Ubiera
  • Patent number: 9610284
    Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: April 4, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
  • Patent number: 9605058
    Abstract: The invention relates to antibodies which treat diseases in which human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and/or ENA-78 are implicated.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 28, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Alexander Harrison Taylor, John Richard White, Yu Xu
  • Patent number: 9597294
    Abstract: A continuous dosage form coating apparatus uses vibrational impulses to maintain a dosage forms in a fluid state to expose them to a coating material atomized by spraying.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 21, 2017
    Assignee: GlaxoSmithKline LLC
    Inventor: Frederick Henry Fiesser
  • Patent number: 9598420
    Abstract: Benzodiazepine compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: March 21, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: James Bailey, Romain Luc Marie Gosmini, Olivier Mirguet, Jason Witherington
  • Patent number: D824256
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: July 31, 2018
    Assignee: GlaxoSmithKline LLC
    Inventors: Jamie Trafford Stone, Jonathan Norman Robert Hodges